Filing Flows › Pediatrix Medical Group (MD) › Guidance & outlook
Pediatrix Medical Group (MD) guidance and outlook
Pediatrix Medical Group (MD) raised its guidance on Oct 29, 2026: EBITDA $290M–$300M for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| EBITDA | FY2026 | $290M–$300M | raised |
From the earnings release filed Oct 29, 2026 (8-K on EDGAR).
Pediatrix Medical Group's latest quarter
Pediatrix Medical Group, Q3 2026: revenue $501M (+2% year over year), operating margin 13.0%, net earnings $47.0M, operating cash flow $117M. The chart follows the revenue to costs, profit and cash.
Questions
Did Pediatrix Medical Group raise or lower its guidance?
Pediatrix Medical Group (MD) raised its guidance on Oct 29, 2026: EBITDA $290M–$300M for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.